BioAlliance Pharma and Topotarget Merger Forms New Orphan Oncology Company
BioAlliance Pharma and Topotarget will merge their complementary pipelines of late-stage oncology products.
BioAlliance Pharma, a Paris, France-based company that specializes in the development of drugs within orphan oncology diseases, and Topotarget, a Scandinavian-based biopharmaceutical company, reported their intention to merge to create an orphan oncology company with complementary pipelines of late-stage products addressing important unmet medical needs. The merger agreement has been unanimously approved by the Boards of Directors of both companies. Under the terms of the merger agreement, BioAlliance Pharma will be the continuing company.
Topotarget’s primary product, belinostat, is a pan-HDAC (histone deacetylase) inhibitor. Belinostat is in a pre-registration phase with FDA for the treatment of relapsed or refractory PTCL (peripheral T-cell lymphoma). The compound has potential for being explored into other rare cancer indications within hematology and solid tumors. Topotarget holds the exclusive rights to these products outside North America and India.
BioAlliance Pharma has two products in late-stage development. Livatag (doxorubicin Transdrug) is currently in a phase III clinical trial in primary liver cancer. Validive (clonidine Lauriad) was granted Fast Track Designation by FDA for the prevention and treatment of oral mucositis induced by anticancer treatments in January 2014, and preliminary data from an international phase II trials are expected in 2014. BioAlliance Pharma has two drugs based on its proprietary Lauriad muco-adhesive technology currently registered in Europe and the US.
Source: BioAlliance Pharma
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
